Industry Trends

Clinical Research
Off-shoring: A Country Attractiveness Index for Clinical Trials

By Mark P. Mathieu
For many years, pharmaceutical companies have been off-shoring manufacturing operations to lower-cost countries. Healthy margins and strong risk aversion have afforded pharmaceutical companies the luxury of staying close to home, for all but manufacturing activities. As financial pressures increase, pharmaceutical executives are finding that going offshore is not only less risky than it once was, but also too attractive to ignore.  Read More




OmniComm Strives to be a Tier I eClinical Player



By Ann Neuer

October 20, 2009 | OmniComm Systems is on a roll.  In a few short years, it has essentially come from nowhere and is now positioned as the Number 3 electronic data capture (EDC) player, behind the 800-pound gorillas: Phase Forward and Medidata.   Sales contracts for TrialMaster, the company’s flagship EDC product, have jumped from $4.8 million in 2006 to $18.1 million in 2008, with continued healthy growth slated for 2009.

Stephen_Johnson
Stephen Johnson
“We want to become a Tier I company”, says Stephen Johnson, Chief Operating Officer.  To reach this goal, OmniComm is executing its ambitious plan to grow organically through ramping up internal resources, and inorganically by making acquisitions to expand its product offerings.

To fuel organic growth, the company has spent the better part of three years building infrastructure, and bringing in the right people.  “We’ve gone from a staff of 25 to 105, and revamped our sales team.  We’ve added a new marketing person, and created a consulting group.  Our Help Desk now operates in eight languages, we’ve opened offices outside the U.S., and we’ve added a clinical services support team to oversee all of the operations when we build a study for our customers.  We think this is a differentiator,” Johnson comments.

The inorganic growth—the acquisitions—is intended to help OmniComm move beyond its EDC roots to become an eClinical company.  Within two years the company hopes to have a fully integrated suite of eClinical applications that will share a single data model across all applications.  According to Johnson, no EDC company has been able to completely pull that off yet.

To build its integrated eClinical solution, OmniComm acquired the EDC business of eResearch Technology (ERT) in June; and in August, the company acquired the EDC assets of Logos Technologies, a provider of Phase I EDC software.

The ERT acquisition was a huge win for OmniComm, which now has a clinical data management system (CDMS), a clinical trial management system (CTMS), a safety module, and a front-end portal.  ERT also brings more of a global presence with its 15 European customers. 

Another key benefit of the acquisition is the jumpstarting of OmniComm’s effort to expand beyond its hosted software-as-a-service (SaaS) business model to include a more profitable technology transfer mode of operation.  “Tech” transfer refers to an option in which the customer pays licensing fees to use software and then builds and administers its own studies.  It is part of the company’s “Crawl, Walk, Run” business model, which gives customers a phased approach to bringing EDC operations in-house.

Johnson explains that tech transfer is highly profitable as it requires few resources beyond providing implementation and validation services, and a Help Desk.  This model represents approximately 95% of its newly acquired ERT business, which is the exact opposite of OmniComm’s mostly SaaS business model, a very resource-intensive and less profitable approach.   

“The ERT deal almost jumped us overnight to a 60-40 mix of SaaS to tech transfer.  Our goal is to become a 50-50 mix of hosted services and tech transfer options to be a more balanced organization,” says Johnson. 

The Logos acquisition offers specialty EDC software that focuses solely on Phase I, a niche market with few players.  In these small studies, data may need to be captured at the bedside at rigidly controlled intervals, such as five minutes, ten minutes, thirty minutes, etc., and in a busy Phase I site, it is easy for staff to miss these collection times.  The Logos product allows the data to be captured in a handheld device that alerts the staff to timepoints that can be tracked up to the minute, and can also be integrated with bar code scanners and laboratory instrumentation.

In December, OmniComm is releasing a Web-based version of the Logos application, and in Q1 2010, the company plans to release an integration of the application with TrialMaster.  

With the new resources from ERT and Logos, OmniComm is hoping to realize it goal of coming out with a major release within 18 to 24 months.  “We are in the process of re-writing all of the applications on a single unified platform,” Johnson explains.

Going forward, OmniComm is actively seeking additional acquisitions, and is currently in negotiations.

Click here to log in.

0 Comments

Add Comment

Text Only 2000 character limit

Page 1 of 1

White Papers & Special Reports

Life Science Webcasts & Podcasts

medidata podcast #8 Meeting Today’s Challenges in Clinical Trial Supply Management
Sponsored by: Medidata Solutions Worldwide  

Setting up and managing the clinical trial involves many complex procedures. Among the most challenging are planning and executing the logistics of the trial’s clinical supplies. This podcast focuses in depth on the following topics which trace current practices and future evolution of this crucial aspect of clinical trials:

  • Current practices in clinical trial logistics
  • Comparing advances in clinical supply practices to  other aspects of clinical trials 
  • Where current practices fall short of meeting the challenges
  • Trends and evolving improvements that may change the way logistics are conducted

Listen Now  


More Podcasts

Job Openings

tessella logo 
Scientific Software Engineer
Boston MA
$70,000 to $95,000
 

Tessella delivers software engineering and consulting services to leading pharmaceutical and biotech companies. We are recruiting Software Engineersto work with skilled bioinformaticians and scientists to identify business needs and recommend and develop technical solutions. Applicants require BS, MS or PhD in bioinformatics, biology or chemistry and 2+ years of software development in either: Java, C#, C++, C or VB.NET. 

Apply at http://jobs.tessella.com   

 

oxford nanopore logo 


 Early Access Collaborations Managers
Oxford Nanopore Technologies is developing a novel technology, GridIONTM for the direct, electronic analysis of DNA/RNA and other analytes.  As the system approaches the market, we are building a team of technically knowledgeable, highly motivated candidates with excellent customer service and facilitation skills to join our company as Collaboration Managers.  This is a unique opportunity to work with world-leading genomics customers throughout the early adoption phase of a new generation of DNA sequencing technology.. This is a facilitative, enabling role with responsibility for managing technology development collaborations with key customers at leading genomics institutions.  It will include long term management of the collaboration plan and milestones and associated meetings and documentation. Click here to find out more and apply   

Oxford Nanopore's GridION technology, VP, Sales and Marketing Oxford Nanopore Technologies is a fast-moving technology company that is developing a novel electronic molecular analysis technology. The technology is adaptable for the analysis of DNA/RNA, proteins, chemicals and other molecules.  It is therefore suitable for use in a variety of markets including scientific research and clinical applications.  As the technology approaches the market, Oxford Nanopore is seeking a visionary VP of sales and marketing to join the senior team.  The candidate will embrace the opportunities afforded by entering the market with a truly disruptive technology that has the potential to expand the number of users and the variety of applications in each target market.  This is a rare opportunity to influence the commercial strategy at an early phase of its commercial lifetime, in a well funded company.  Oxford Nanopore welcomes applications from candidates with a track record of high-level strategic commercial  leadership, who wish to apply a fresh approach to existing markets.  Experience in Life Sciences/DNA sequencing is central to this role, however we will consider your application if you have experience of disruptive technologies in other related industries.  We are particularly interested in candidates with strong expertise in the use of digital technologies for sales and marketing of scientific/technical products.  Click to  Apply  


 

Related Resources & Products




Sponsored Links

For reprints and/or copyright permission, please contact  Tim McLucas, (781) 972-1342, tmclucas@healthtech.com .